{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:11:13Z","timestamp":1759921873564,"version":"build-2065373602"},"reference-count":40,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT)","award":["PTDC\/QUI-QIN\/0146\/2020","UIDB\/00100\/2020","LA\/P\/0056\/2020","UID\/Multi\/04349\/2020","SFRH\/BD\/135915\/2018","PRT\/BD\/154855\/2023","2022.00028.CEECIND\/CP1722\/CT0005","2020.02383.CEECIND\/CP1595\/CT0005","2022.15449.UT.","2021.09137.CBM"],"award-info":[{"award-number":["PTDC\/QUI-QIN\/0146\/2020","UIDB\/00100\/2020","LA\/P\/0056\/2020","UID\/Multi\/04349\/2020","SFRH\/BD\/135915\/2018","PRT\/BD\/154855\/2023","2022.00028.CEECIND\/CP1722\/CT0005","2020.02383.CEECIND\/CP1595\/CT0005","2022.15449.UT.","2021.09137.CBM"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia and Campus France","award":["PTDC\/QUI-QIN\/0146\/2020","UIDB\/00100\/2020","LA\/P\/0056\/2020","UID\/Multi\/04349\/2020","SFRH\/BD\/135915\/2018","PRT\/BD\/154855\/2023","2022.00028.CEECIND\/CP1722\/CT0005","2020.02383.CEECIND\/CP1595\/CT0005","2022.15449.UT.","2021.09137.CBM"],"award-info":[{"award-number":["PTDC\/QUI-QIN\/0146\/2020","UIDB\/00100\/2020","LA\/P\/0056\/2020","UID\/Multi\/04349\/2020","SFRH\/BD\/135915\/2018","PRT\/BD\/154855\/2023","2022.00028.CEECIND\/CP1722\/CT0005","2020.02383.CEECIND\/CP1595\/CT0005","2022.15449.UT.","2021.09137.CBM"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Cancer remains one of the major challenges of our century. Organometallic ruthenium complexes are gaining recognition as a highly promising group of compounds in the development of cancer treatments. Methods: Building on the auspicious results obtained for [Ru(\u03b75-C5H5)(PPh3)(bipy)][CF3SO3] (TM34), our focus has shifted to examining the effects of incorporating bioactive ligands into the TM34 framework, particularly within the cyclopentadienyl ring. Results: In this study, we report the synthesis and characterization of two new ruthenium(II) complexes with the general formula [Ru(\u03b75-C5H4CCH3=R)(PPh3)(bipy)][CF3SO3], where R represents a nicotinic acid derivative (NNHCO(py-3-yl)) (1) or an isoniazid derivative (NNHCO(py-4-yl)) (2). The complexes were fully characterized using a combination of spectroscopic techniques and computational analysis, revealing the presence of E\/Z-hydrazone isomerism. Stability studies confirmed the robustness of both complexes in biological media, with compound 1 maintaining good stability in buffer solutions mimicking physiological (pH 7.4) and tumor-like (pH 6.8) environments. The cytotoxicity of the complexes was evaluated in vitro in several human cancer cell lines, namely melanoma (A375), alveolar adenocarcinoma (A549), epidermoid carcinoma (A431), and breast cancer (MDA-MB 231). Conclusions: Both compounds exhibited moderate to high cytotoxic activity, with complex 1 showing a greater propensity to induce cell death, particularly in the A431 and MDA-MB 231 cell lines.<\/jats:p>","DOI":"10.3390\/ph18010097","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T07:35:47Z","timestamp":1736840147000},"page":"97","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synthesis and Evaluation of Cytotoxic Activity of RuCp(II) Complexes Bearing (Iso)nicotinic Acid Based Ligands"],"prefix":"10.3390","volume":"18","author":[{"given":"B\u00e1rbara","family":"Marques","sequence":"first","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Institute of Molecular Sciences, Faculdade de Ci\u00eancias, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5979-1810","authenticated-orcid":false,"given":"Diogo M.","family":"Engr\u00e1cia","sequence":"additional","affiliation":[{"name":"Centro de Ci\u00eancias e Tecnologias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, 2695-066 Bobadela LRS, Portugal"}]},{"given":"Jo\u00e3o Franco","family":"Machado","sequence":"additional","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Institute of Molecular Sciences, Faculdade de Ci\u00eancias, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7459-0993","authenticated-orcid":false,"given":"Jaime A. S.","family":"Coelho","sequence":"additional","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Institute of Molecular Sciences, Faculdade de Ci\u00eancias, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal"},{"name":"Departamento de Qu\u00edmica e Bioqu\u00edmica, Faculdade de Ci\u00eancias, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0646-1687","authenticated-orcid":false,"given":"Filipa","family":"Mendes","sequence":"additional","affiliation":[{"name":"Centro de Ci\u00eancias e Tecnologias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, 2695-066 Bobadela LRS, Portugal"},{"name":"Departmento de Engenharia e Ci\u00eancias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, 2695-066 Bobadela LRS, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0233-8243","authenticated-orcid":false,"given":"T\u00e2nia S.","family":"Morais","sequence":"additional","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Institute of Molecular Sciences, Faculdade de Ci\u00eancias, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal"},{"name":"Departamento de Qu\u00edmica e Bioqu\u00edmica, Faculdade de Ci\u00eancias, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kerpel-Fronius, S. (2006). Cisplatin and Its Analogues for Cancer Chemotherapy. Analogue-Based Drug Discovery, Wiley.","DOI":"10.1002\/3527608001.ch19"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1039\/D1CS00468A","article-title":"Metallodrugs in Cancer Nanomedicine","volume":"51","author":"Wang","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.13005\/bpj\/1608","article-title":"Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin","volume":"12","author":"Aldossary","year":"2019","journal-title":"Biomed. Pharmacol. J."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Martinho, N., Santos, T.C.B., Florindo, H.F., and Silva, L.C. (2019). Cisplatin-Membrane Interactions and Their Influence on Platinum Complexes Activity and Toxicity. Front. Physiol., 10.","DOI":"10.3389\/fphys.2018.01898"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1021\/acs.inorgchem.3c03696","article-title":"Exploiting Co(III)-Cyclopentadienyl Complexes To Develop Anticancer Agents","volume":"63","author":"Cordeiro","year":"2024","journal-title":"Inorg. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lu, L., Liu, L.J., Chao, W.C., Zhong, H.J., Wang, M., Chen, X.P., Lu, J.J., Li, R.N., Ma, D.L., and Leung, C.H. (2015). Identification of an Iridium(III) Complex with Anti-Bacterial and Anti-Cancer Activity. Sci. Rep., 5.","DOI":"10.1038\/srep14544"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/med.20168","article-title":"Gold Compounds as Anticancer Agents: Chemistry, Cellular Pharmacology, and Preclinical Studies","volume":"30","author":"Nobili","year":"2010","journal-title":"Med. Res. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1039\/C5CS00486A","article-title":"Ferrocifen Type Anti Cancer Drugs","volume":"44","author":"Jaouen","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejmech.2017.04.007","article-title":"Platinum, Palladium, Gold and Ruthenium Complexes as Anticancer Agents: Current Clinical Uses, Cytotoxicity Studies and Future Perspectives","volume":"142","author":"Rilak","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8891","DOI":"10.1002\/chem.202100438","article-title":"Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer","volume":"27","author":"Nayeem","year":"2021","journal-title":"Chem. A Eur. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1021\/acs.chemrev.8b00271","article-title":"Toward Multi-Targeted Platinum and Ruthenium Drugs\u2014A New Paradigm in Cancer Drug Treatment Regimens?","volume":"119","author":"Kenny","year":"2019","journal-title":"Chem. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.2147\/DDDT.S275007","article-title":"Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives","volume":"14","author":"Lee","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e202201645","DOI":"10.1002\/slct.202201645","article-title":"Ruthenium Complexes as Potential Cancer Cell Growth Inhibitors for Targeted Chemotherapy","volume":"7","author":"Katheria","year":"2022","journal-title":"ChemistrySelect"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lin, K., Zhao, Z.Z., Bo, H.B., Hao, X.J., and Wang, J.Q. (2018). Applications of Ruthenium Complex in Tumor Diagnosis and Therapy. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01323"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ejmech.2018.03.015","article-title":"Detailed Account on Activation Mechanisms of Ruthenium Coordination Complexes and Their Role as Antineoplastic Agents","volume":"150","author":"Pal","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2022.40.16_suppl.3031","article-title":"BOLD-100-001 (TRIO039): A Phase 1b Dose-Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Advanced Gastrointestinal Solid Cancers: Interim Safety, Tolerability, and Efficacy","volume":"40","author":"Spratlin","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10637-014-0179-1","article-title":"Phase I\/II Study with Ruthenium Compound NAMI-A and Gemcitabine in Patients with Non-Small Cell Lung Cancer after First Line Therapy","volume":"33","author":"Leijen","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Alessio, E., and Messori, L. (2019). NAMI-A and KP1019\/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry. Molecules, 24.","DOI":"10.3390\/molecules24101995"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/acs.chemrev.8b00211","article-title":"Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433","volume":"119","author":"Monro","year":"2019","journal-title":"Chem. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e000154","DOI":"10.1136\/esmoopen-2016-000154","article-title":"Safety and Activity of IT-139, a Ruthenium-Based Compound, in Patients with Advanced Solid Tumours: A First-in-Human, Open-Label, Dose-Escalation Phase i Study with Expansion Cohort","volume":"1","author":"Burris","year":"2016","journal-title":"ESMO Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ejmech.2017.11.059","article-title":"Novel Ruthenium Methylcyclopentadienyl Complex Bearing a Bipyridine Perfluorinated Ligand Shows Strong Activity towards Colorectal Cancer Cells","volume":"143","author":"Teixeira","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4155\/fmc.16.7","article-title":"Tracking Antitumor Metallodrugs: Promising Agents with the Ru(II)- and Fe(II)-Cyclopentadienyl Scaffolds","volume":"8","author":"Morais","year":"2016","journal-title":"Future Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9164","DOI":"10.1021\/ic201388n","article-title":"A Potent Ruthenium(II) Antitumor Complex Bearing a Lipophilic Levonorgestrel Group","volume":"50","author":"Ruiz","year":"2011","journal-title":"Inorg. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1021\/jm070039f","article-title":"Development of Ruthenium Antitumor Drugs That Overcome Multidrug Resistance Mechanisms","volume":"50","author":"Vock","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"119858","DOI":"10.1016\/j.ica.2020.119858","article-title":"Ruthenium and Iridium Based Mononuclear and Multinuclear Complexes: A Breakthrough of Next-Generation Anticancer Metallopharmaceuticals","volume":"512","author":"Kar","year":"2020","journal-title":"Inorganica Chim. Acta"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ccr.2015.06.014","article-title":"The Development of RAPTA Compounds for the Treatment of Tumors","volume":"306","author":"Murray","year":"2016","journal-title":"Coord. Chem. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2533\/chimia.2007.704","article-title":"The Design of Organometallic Ruthenium Arene Anticancer Agents","volume":"61","author":"Dougan","year":"2007","journal-title":"Chimia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2174\/1871520616666160922165133","article-title":"In Vivo Performance of a Ruthenium-Cyclopentadienyl Compound in an Orthotopic Triple Negative Breast Cancer Model","volume":"17","author":"Mendes","year":"2016","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00775-014-1120-y","article-title":"Anticancer Activity of Structurally Related Ruthenium(II) Cyclopentadienyl Complexes","volume":"19","author":"Mendes","year":"2014","journal-title":"J. Biol. Inorg. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.2174\/1871520619666190318152726","article-title":"Antitumour and Toxicity Evaluation of a Ru(II)-Cyclopentadienyl Complex in a Prostate Cancer Model by Imaging Tools","volume":"19","author":"Gano","year":"2019","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1039\/D4DT00497C","article-title":"Dual FGFR-Targeting and PH-Activatable Ruthenium\u2013Peptide Conjugates for Targeted Therapy of Breast Cancer","volume":"53","author":"Pires","year":"2024","journal-title":"Dalton Trans."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8086253","DOI":"10.1155\/2021\/8086253","article-title":"Antituberculosis Drugs (Rifampicin and Isoniazid) Induce Liver Injury by Regulating NLRP3 Inflammasomes","volume":"2021","author":"Su","year":"2021","journal-title":"Mediat. Inflamm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.freeradbiomed.2019.07.012","article-title":"Molecular Mechanism for the Activation of the Anti-Tuberculosis Drug Isoniazid by Mn(III): First Detection and Unequivocal Identification of the Critical N-Centered Isoniazidyl Radical and Its Exact Location","volume":"143","author":"Qin","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"116767","DOI":"10.1016\/j.taap.2023.116767","article-title":"Anticancer Effect of Aromatic Isoniazid Derivatives in Human Gastric Adenocarcinoma Cells","volume":"481","author":"Barathan","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Li, J., Qu, J., Shi, Y., Perfetto, M., Ping, Z., Christian, L., Niu, H., Mei, S., Zhang, Q., and Yang, X. (2017). Nicotinic Acid Inhibits Glioma Invasion by Facilitating Snail1 Degradation. Sci. Rep., 7.","DOI":"10.1038\/srep43173"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Troll, W. (1993). Prevention of Cancer by Vitamin B3 (Nicotinamide and Nicotinic Acid). Protease Inhibitors as Cancer Chemopreventive Agents, Springer.","DOI":"10.1007\/978-1-4615-2882-1_10"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1039\/C8BM01189C","article-title":"Repurposing Antitubercular Agent Isoniazid for Treatment of Prostate Cancer","volume":"7","author":"Lv","year":"2018","journal-title":"Biomater. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Maximiano, I., Henriques, C., Teixeira, R.G., Marques, F., Valente, A., and Antunes, A.M.M. (2024). Lead to Hit Ruthenium-Cyclopentadienyl Anticancer Compounds: Cytotoxicity against Breast Cancer Cells, Metabolic Stability and Metabolite Profiling. J. Inorg. Biochem., 251.","DOI":"10.1016\/j.jinorgbio.2023.112436"},{"key":"ref_39","unstructured":"Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Scalmani, G., Barone, V., Petersson, G.A., and Nakatsuji, H. (2019). Gaussian 16, Revision C.01, Gaussian, Inc.. Gaussian 09."},{"key":"ref_40","unstructured":"(2024, August 15). CYLview Visualization Software. Available online: http:\/\/www.cylview.org\/."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/1\/97\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:28:36Z","timestamp":1759919316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/1\/97"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["ph18010097"],"URL":"https:\/\/doi.org\/10.3390\/ph18010097","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2025,1,14]]}}}